Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
Year: 2015
Type: article
Abstract: Identified as prognostic factors for overall survival; selected chemotherapy, as recorded in the case report form, was also identified as a prognostic factor.
Source: Journal of Clinical Oncology
Institutions: Fundación Instituto Valenciano de Oncología, Spanish Ovarian Cancer Research Group, Assistance Publique – Hôpitaux de Paris, Hôpital Tenon, Université Pierre-et-Marie-Curie, Arbeitsgemeinschaft Gynäkologische Onkologie Studiengruppe, Instituto Nazionale Tumori Regina Elena, KU Leuven, University Medical Center Utrecht, National and Kapodistrian University of Athens, Hellenic Cooperative Oncology Group, F. Hoffmann-La Roche AG, Université Paris Descartes
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funder: F. Hoffmann-La Roche
OpenAlex ID: W2130659669
